London, 09 October 2014: TechNavio, the independent tech-focused global research firm, has published a report on the Global ADHD Drugs Market 2014-2018, which is expected to post a CAGR of 5.33 percent during the forecast period of 2013-2018.
ADHD is a psychiatric disorder most commonly diagnosed in children. However, adults have also been reported to be diagnosed with ADHD. ADHD patients suffer from several problems including hyperactivity, impulsiveness, and lack of focus and concentration. It is more prevalent in boys than girls. It is believed to be linked with genetic and environmental causes and a decrease in the extraneuronal levels of norepinephrine and dopamine. ADHD can be managed by counseling, medications, and lifestyle changes.
“Companies expect to gain a competitive advantage by outsourcing some processes as manufacturing costs can be reduced,” says Faisal Ghaus, Vice President of TechNavio.
“Alliances allow companies to concentrate on their core activities such as the development of molecules.”
Key Market Drivers
- Unmet Need
- Launch of Pipeline Drugs
- Rise in Prevalence
- Availability of Diagnostic Tools
Key Market Trends
- Increase in Awareness
- Strategic Alliances
- Use of Generic Antidepressants
Key Market Vendors
- Eli Lilly and Co.
- Janssen Pharmaceuticals Inc.
- Novartis AG
- Shire plc
To define the market circumstances in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
